Prospective follow-up study of golimumab treatment in psoriatic arthritis

Phase 4

• Conditions: psoriatic arthritis; 10003816; 10023213; 10014982

• Registration Number: NL-OMON37425
• Lead Sponsor: Jan van Breemen Instituut

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 100

Inclusion Criteria

patients with psoriatic arthritis in whom golimumab treatment is started
written informed consent

Exclusion Criteria

contraindications against golimumab treatment

Study & Design

• Study Type: Observational non invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>- ACR20 response: 20% improvement or 10 point decrease on 100mm VASscales<br /><br>- PASI improvement<br /><br>- MDA status</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>-The number of adverse events (infections, malignancies, mortality)<br /><br>- LEI Improvement<br /><br>-Number of digits with dactylitis<br /><br>-Number of nails with nail psoriasis<br /><br>-ESR and/or CRP<br /><br>-The lipid profile<br /><br>-inflammation processes<br /><br>-Relation between genetic polymorphisms and the efficacy of golimumab<br /><br>-Radiographic progression<br /><br>-Changes in bone mineral density.</p><br>